Building Effective Health Economic Outcomes Research (HEOR) Teams
How to build an effective health economic and outcomes research team
Health Economic and Outcomes Research (HEOR) teams play a critical market access role from refining clinical research and building a brand’s value proposition to informing post-marketing reviews. As the demands of payer, regulator and Health Technology Assessment (HTA) agencies grow, what does a modern and effective HEOR team look like in 2016?
This expert report analyses the growing pressure points on HEOR teams and identifies the essential staff talents, organisational positioning, external providers and evaluation criteria needed to deliver persuasive HEOR in a demanding market.
“The role of HEOR is to enable long-term market access to therapies, not only the strict cost-utility analysis but going further and helping market access teams to provide an understanding of the value of a therapy.”
Vice President, Market Access, Health Policy and Medical Affairs
Top 10 Vaccines Manufacturer
Reasons to Purchase Answering key questions
Payer/HTA pressures: Growing and specific payer/HTA requests for data and supporting evidence is demanding on an HEOR team’s time. How can companies optimise their resources?
Where’s the money? Investment in HEOR is increasing, but demands and workloads are expanding even faster. Can pharma get a head of the funding curve?
Early engagement: How, when and why should pharma involve HEOR teams in clinical research planning?
HEOR Organisation: Medical affairs? Market access? Does it matter?
Outside help: In what circumstances can external consultants bring value to HEOR and what are the key management issues concerning their engagement?
Skills gap: How can you recruit, train, reward and retain hard-to-come-by HEOR staff and should employers be looking beyond health economists for talent?
Performance Management: What evaluation techniques and metrics can be employed to measure HEOR team performance?
Key Topics Explored:
Payer/HTA demands for specific evidence and data is outstripping pharma’s investment in HEOR. Given its importance for commercial success, isn’t it time pharma rethought the level of investment in HEOR?
Finding staff that combine good technical skill with capabilities for delivering complex data persuasively to multiple stakeholders is a big ask. Where should recruiters be looking and what are the essential skills needed?
Opinion differs about where HEOR should sit organisationally, but cross-functional teams are critical to achieving the end result.
Not just bean counters: evaluating HEOR team members and team performance needs to look at much more than activity levels, so what are the options for measuring success?
Expert contributors to this report include senior HEOR and market access professionals working in leading pharma companies. To ensure candid views were expressed their identities have been kept anonymous.
A Vice President, Market Access, Health Policy and Medical Affairs within a top 10 vaccine manufacturer
A Senior Vice President, Global Regulation, Healthcare Policy and Corporate Affairs within a top 50 global pharmaceutical manufacturer
A Senior Health Economics and Outcomes Research Manager, UK and Ireland within a top 50 global pharmaceutical manufacturer
A Senior Director, Global Outcomes & Epidemiology within a top 50 global pharmaceutical manufacturer
A Health Economics Director, Europe, within a top 50 global pharmaceutical manufacturer
A Vice President, Health Economics and Outcomes Research within a top 10 global pharmaceutical manufacturer
A Head of Market Access, Oncology, UK, within a top 10 global pharmaceutical manufacturer
A Director, Medical Policy-Access Research at a top 10 global pharmaceutical manufacturer
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence. FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success. FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.